Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 1891 to 1900 of 2581 total matches.
In Brief: Airborne
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005 (Issue 1199)
The Medical Letter
®
On Drugs and Therapeutics
1
FORWARDING OR COPYING IS A VIOLATION OF U.S ...
Patients may be asking about Airborne, a dietary supplement that is being heavily promoted for prevention and treatment of colds. It contains 7 herbal extracts, 3 vitamins, 2 amino acids, selenium, zinc and many other ingredients. Airborne Jr is available for children. There are some concerns. First, there is no conclusive evidence that this product or any of its ingredients prevents colds or shortens their duration. Second, the adult tablet contains 1 g of vitamin C, and the directions for use advise taking 1 tablet at the first sign of a cold and repeating the dose every 3 hours as...
Clarification: Half-Life of Heroin
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016 (Issue 1489)
The Medical Letter®
on Drugs and Therapeutics
Volume 58 (Issue 1489) February 29, 2016
Published ...
A reader expressed concern that a statement in our article Naloxone (Narcan) Nasal Spray for Opioid Overdose (Med Lett Drugs Ther 2016; 58:1) might be misleading. We stated that heroin has a half-life of 2-6 minutes, which is correct, but heroin is a prodrug that is rapidly metabolized to 6-acetylmorphine and morphine. The risk of respiratory depression is related to those active metabolites, and it may persist well beyond the clearance of heroin from the blood.
In Brief: Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020 (Issue 1590)
-mediated amyloid
cardiomyopathy (ATTR-CM). Tafamidis is the first drug
to be approved ...
The FDA has approved tafamidis, an oral transthyretin stabilizer, in 2 different formulations (see Table 1) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Tafamidis is the first drug to be approved in the US for this indication. Patisiran (Onpattro), a transthyretin-directed small interfering RNA, and inotersen (Tegsedi), a transthyretin-directed antisense oligonucleotide, were both recently approved for hereditary transthyretin amyloid polyneuropathy.THE DISEASE — ATTR-CM is a progressive life-threatening disease caused by destabilization of the...
COVID-19 Updates
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
on vaccines and drugs for COVID-19 can
be found in the COVID-19 Resources section of our website ...
On January 3, the FDA amended its Emergency
Use Authorization (EUA) for the Pfizer-BioNTech
COVID-19 vaccine (Comirnaty) to incorporate the
following changes. The anti-SARS-CoV-2 antibody combinations
casirivimab plus imdevimab (REGEN-COV) and
bamlanivimab plus etesevimab are not active
against the Omicron variant of SARS-CoV-2.
Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
, and hepatotoxity are
common with use of the drug.
PREGNANCY AND LACTATION — In animal studies,
administration ...
The alkylating agent lurbinectedin (Zepzelca – Jazz)
has received accelerated approval from the FDA
for treatment of metastatic small-cell lung cancer
(SCLC) in adults with disease progression on or after
platinum-based chemotherapy. Accelerated approval
was based on the overall response rate and duration
of response. About 13-15% of lung cancers are small-cell
cancers. Most SCLCs occur in patients who are
current or former smokers.
Sinemet CR For Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991 (Issue 854)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Controlled-release carbidopa/levodopa (Sinemet CR - Dupont Pharma) was recently approved by the US Food and Drug Administration for treatment of Parkinson's disease. The new formulation of this old combination (Sinemet) has the drugs suspended in a polymeric matrix that erodes slowly in the gastrointestinal tract.
Fluoxetine Sarafem For Premenstrual Dysphoric Disorder
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001 (Issue 1096)
The Medical Letter
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 Main ...
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) previously sold only as Prozac, is now also marketed as Sarafem for treatment of premenstrual dysphoric disorder (PMDD). Generic fluoxetine is expected to be available sometime this year.
Dexmethylphenidate (Focalin) For ADHD
The Medical Letter on Drugs and Therapeutics • May 13, 2002 (Issue 1130)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Dexmethylphenidate (Focalin - Novartis), a new formulation of methylphenidate (Ritalin, and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is the d-threo-enantiomer of racemic methylphenidate. "Now the right half may be all your patients need," said a recent ad. Focalin is the third new methylphenidate formulation marketed in the last two years.
Rasburicase (Elitek) for Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
The Medical Letter
On Drugs and Therapeutics
www.medicalletter.org
Published by The Medical ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Parcopa: A Rapidly Dissolving Formulation of Carbidopa/Levodopa
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005 (Issue 1201)
Letter
®
On Drugs and Therapeutics
IN THIS ISSUE
Volume 47 (Issue 1201)
January 31, 2005 ...
An orally dissolving, immediate-release tablet formulation of carbidopa/levodopa (Parcopa - Schwarz) that can be taken without water is now available for treatment of Parkinson's disease.